Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
about
Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Delayed initiation of front-li ...... of the ENACT trial in Lebanon.
@en
Delayed initiation of front-li ...... of the ENACT trial in Lebanon.
@nl
type
label
Delayed initiation of front-li ...... of the ENACT trial in Lebanon.
@en
Delayed initiation of front-li ...... of the ENACT trial in Lebanon.
@nl
prefLabel
Delayed initiation of front-li ...... of the ENACT trial in Lebanon.
@en
Delayed initiation of front-li ...... of the ENACT trial in Lebanon.
@nl
P2093
P2860
P1476
Delayed initiation of front-li ...... of the ENACT trial in Lebanon.
@en
P2093
Azzam Ziade
Fadi S Farhat
Miguel R Abboud
Nader Kassem
Rami A Mahfouz
Zaher K Otrock
Zahera Fahed
P2860
P2888
P304
P356
10.1007/S12185-012-1168-9
P577
2012-09-09T00:00:00Z